Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study
Prognosis of 6644 resected non-small cell lung cancers in Japan: A Japanese lung cancer registry study
复制标题
DOI：
10.1016/j.lungcan.2005.05.021
复制
发表时间：
2005-11-01
期刊：
影响因子：
5.3
通讯作者：
Miyaoka, E
中科院分区：
文献类型：
--
作者：
Goya, T;Asamura, H;Miyaoka, E
对于肺癌TNM分期系统的预定未来修订，重要的是，目前的1997年版本进行评估，在一个大的人口。2001年，日本肺癌登记联合委员会向320家日本机构发送了一份关于1994年接受原发性肺肿瘤切除术患者的预后和临床病理特征的问卷。我们收集了来自303家机构（94.7%）的7408例患者的数据。其中，6644例非小细胞组织学患者的预后进行了研究。全组5年生存率为52.6%。按临床（c-）分期列出的5年生存率如下：IA为72.1%（n = 2423），49.9%为IB IIA组为48.7%（n = 150），IIB组为40.6%（n = 746），IIIA组为35.8%（n = 1270），IIIB组为28.0%（n = 366），IV组为20.8%（n = 147）。除IB期与IIA期、IIIB期与IV期外，其余各期间的预后差异均有统计学意义。按病理（p-）分期列出的5年生存率如下：IA为79.5%（n = 2009），IB为60.1% IIA组为59.9%（n = 232），IIB组为42.2%（n = 757），IIIA组为29.8%（n = 1250），IIIB组为19.3%（n = 719），IV组为20.0%（n = 259）。除IB期与IIA期、IIIB期与IV期外，其余各期间的预后差异均有统计学意义。IB期和IIA期的生存曲线在c-和p-设置中几乎重叠。这些结果表明，目前的IB和IIA阶段应合并为同一阶段类别。另外，目前的TNM分期系统似乎很好地描述了非小细胞肺癌的分期特异性预后。今后的修订应侧重于第一和第二阶段的细分。(c)2005爱思唯尔爱尔兰有限公司保留所有权利。
For the scheduled future revision of the TNM staging system for lung cancer, it is important that the present 1997 version be evaluated in a large population. In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a questionnaire to 320 Japanese institutions regarding the prognosis and clinicopathological profiles of patients who underwent the resection for primary lung neoplasms in 1994. We compiled the data for 7408 patients from 303 institutions (94.7%). Among these, 6644 patients with non-small cell histology were studied in terms of prognosis. The 5-year survival rate of the entire group was 52.6%. The 5-year survival rates by clinical (c-) stage were as follows: 72.1% for IA (n = 2423), 49.9% for IB (n = 1542), 48.7% for IIA (n = 150), 40.6% for IIB (n = 746), 35.8% for IIIA (n = 1270), 28.0% for IIIB (n = 366) and 20.8% for IV (n = 147). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The 5-year survival rates by pathological (p-) stage were as follows: 79.5% for IA (n = 2009), 60.1% for IB (n = 1418), 59.9% for IIA (n = 232), 42.2% for IIB (n = 757), 29.8% for IIIA (n = 1250), 19.3% for IIIB (n = 719) and 20.0% for IV (n = 259). The difference in prognosis between neighboring stages was significant except for between IB and IIA and between IIIB and IV. The survival curves of stages IB and IIA were almost superimposed in both c- and p-settings. These findings indicated that the present stages IB and IIA should be merged into the same stage category. Otherwise, the present TNM staging system seemed to well characterize the stage-specific prognosis in non-small cell lung cancer. The future revision should focus on the subdivision of stages I and II. (c) 2005 Elsevier Ireland Ltd. All rights reserved.